No stone goes unturned

Ontogeny Inc. has moved its developmental biology platform into the realm of small molecule therapeutic development. However, the move toward small molecules does not presage an equivalent shift away from protein therapeutics. Instead, the two are complementary, each having specific advantages for certain indications that can further Ontogeny's goal of extracting every possible therapeutic avenue from its platform.

Ontogeny's technology is based on the hedgehog family of induction molecules, regulatory proteins that bind to the surface of cells and activate a variety of developmental changes. The proteins also have activity in adult disorders such as bone and cartilage repair and certain central nervous system (CNS) diseases that benefit from tissue regeneration...